ReviewTranslational cancer research2026
Narrative review-the emerging role, functions, and mechanisms of UFMylation in cancers.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: UFM1 system, i.e., UFMylation, is a newly identified post-translational modification (PTM). Increasing evidence have indicated that defects of UFMylation are implicated in multiple pathological conditions including cancers. Through this narrative review, we aim to provide a comprehensive view for development of therapeutic targets and strategies. Methods: Based on PubMed database, thorough literature research was performed to finish this narrative review. The research strategy was as follows: (ufmylation) AND ((cancer) OR (neoplasm) OR (tumor)). Key Content and Findings: We first summarize recently identified substrates of UFMylation. Next, we focus on and discuss reported molecular mechanisms of UFMylation in tumorigenesis and cancer treatment responses and resistance. In addition, we discuss the role and function of UFMylation in various cancers, mainly in solid tumors. Lastly, we discuss the possible crosstalk between UFMylation and ubiquitination. Conclusions: In the past decades, emerging evidence have shown that UFMylation is crucial for organ development, homeostasis maintenance, inflammation, immunity and metabolism. In addition, the defects of UFMylation, including genetic variants, abnormal expression pattern and somatic copy number alterations, have been reported involved in tumorigenesis, progression and treatment response. With in-depth investigation and research, enzymatic cascades and substrates of UFMylation will be unveiled. Promisingly, UFMylation may be utilized as a biomarker for diagnosis, treatment response assessment, and therapeutic targets in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.